Wang, Yan Law, Wai-Kit Hu, Jian-Shu Lin, Huang-Quan Ip, Tsz-Ming Wan, David Chi-Cheong Discovery of FDA-Approved Drugs as Inhibitors of Fatty Acid Binding Protein 4 Using Molecular Docking Screening We first identified fluorescein, ketazolam, antrafenine, darifenacin, fosaprepitant, paliperidone, risperidone, pimozide, trovafloxacin, and levofloxacin as inhibitors of fatty acid binding protein 4 using molecular docking screening from FDA-approved drugs. Subsequently, the biochemical characterizations showed that levofloxacin directly inhibited FABP4 activity in both the <i>in vitro</i> ligand displacement assay and cell-based function assay. Furthermore, levofloxacin did not induce adipogenesis in adipocytes, which is the major adverse effect of FABP4 inhibitors. FABP 4 activity;docking screening;Binding Protein 4;levofloxacin;Molecular Docking ScreeningWe;acid binding protein 4;ligand displacement assay;FABP 4 inhibitors 2014-11-24
    https://acs.figshare.com/articles/dataset/Discovery_of_FDA_Approved_Drugs_as_Inhibitors_of_Fatty_Acid_Binding_Protein_4_Using_Molecular_Docking_Screening/2232421
10.1021/ci500503b.s003